SGLT-2 Inhibitors and Regenerative Cell Exhaustion

David A Hess; Daniella C Terenzi; Subodh Verma

doi:10.1016/j.cmet.2020.04.003

SGLT-2 Inhibitors and Regenerative Cell Exhaustion

Cell Metab. 2020 May 5;31(5):884-885. doi: 10.1016/j.cmet.2020.04.003. Epub 2020 Apr 16.

Authors

David A Hess¹, Daniella C Terenzi², Subodh Verma³

Affiliations

¹ Division of Vascular Surgery, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, ON, Canada; Molecular Medicine Research Laboratories, Robarts Research Institute, London, ON, Canada; Department of Physiology and Pharmacology, Western University, London, ON, Canada.
² Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, ON, Canada; Insitute of Medical Sciences, University of Toronto, Toronto, ON, Canada.
³ Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, ON, Canada; Insitute of Medical Sciences, University of Toronto, Toronto, ON, Canada; Department of Surgery, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Electronic address: vermasu@smh.ca.

PMID: 32302528
DOI: 10.1016/j.cmet.2020.04.003

Abstract

In response to the Letter by Fadini, Hess et al. discuss the interpretation of their data and the details of the multiparametric analyses employed to measure the changes in circulating provascular cell content in patients with type 2 diabetes receiving empagliflozin compared to placebo treatment.

Publication types

Letter
Comment

MeSH terms

Benzhydryl Compounds
Diabetes Mellitus, Type 2* / drug therapy
Glucosides
Humans
Hypoglycemic Agents
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Stem Cells

Substances

Benzhydryl Compounds
Glucosides
Hypoglycemic Agents
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin